Last Updated : July 10, 2009
Details
FilesGeneric Name:
Lisdexamfetamine dimesylate
Project Status:
Complete
Therapeutic Area:
Attention deficit hyperactivity disorder
Manufacturer:
Shire Canada Inc.
Brand Name:
Vyvanse
Project Line:
Reimbursement Review
Project Number:
SR0171-000
Performance Metric:
N/A — Predated performance metrics
Submission Type:
Initial
Indications:
Attention deficit hyperactivity disorder
Recommendation Type:
Do not list
Final Recommendation:
Files
Last Updated : July 10, 2009